| 00:00:00 | Untitled |
| 00:01:08 | Step into the Light – how Dynamic Light Scattering can Improve the Quality of your Biopharmaceutical DataMichael CavesProduct Technical Specialist for Biophysical Characterisation |
| 00:01:28 | Protein Evolution |
| 00:02:16 | Protein Structure |
| 00:02:32 | Biopharmaceutical Analysis |
| 00:02:53 | Biopharmaceutical Analysis |
| 00:03:06 | Untitled |
| 00:03:36 | Untitled |
| 00:04:07 | Untitled |
| 00:04:09 | Static Light Scattering (SLS) |
| 00:04:32 | Dynamic Light Scattering (DLS) |
| 00:05:06 | Untitled |
| 00:05:25 | Untitled |
| 00:05:47 | Untitled |
| 00:06:01 | Untitled |
| 00:06:08 | Untitled |
| 00:06:10 | Untitled |
| 00:06:12 | Untitled |
| 00:06:38 | The Correlogram |
| 00:07:03 | The Correlogram |
| 00:08:17 | Untitled |
| 00:09:06 | Untitled |
| 00:11:26 | Dynamic Light Scattering Theory Summary |
| 00:11:52 | Untitled |
| 00:11:55 | FDA Draft Guidance 2013 – Immunogenicity |
| 00:12:20 | Biopharmaceutical Stability |
| 00:13:33 | Monitor the Earliest Stages of Aggregation25.0 °C71.5 °C76.5 °C84.0 °C |
| 00:15:02 | Pegylation Analysis |
| 00:16:57 | Real-Time Aggregation |
| 00:17:52 | Antibody Binding Studies |
| 00:18:46 | Antibody Binding Studies |
| 00:20:25 | Purity and Stability Analysis Summary |
| 00:20:51 | Untitled |
| 00:20:53 | FDA Draft Guidance 2013 – Immunogenicity |
| 00:21:30 | Untitled |
| 00:22:43 | Untitled |
| 00:23:34 | Untitled |
| 00:24:41 | Orthogonal Stability Prediction |
| 00:25:19 | Stability Prediction Summary |
| 00:25:37 | Untitled |
| 00:25:40 | The Malvern Zetasizer Range |
| 00:26:59 | DLS Biopharmaceutical Applications |
| 00:27:49 | Thank You for ListeningQuestions? |
| 00:31:56 | Contact Information |
Biopharmaceutical impurities have long been associated with undesirable clinical reactions. It is essential, therefore, that the purity profiles of such drugs are characterized with the most sensitive analysis methods available. Dynamic light scattering is widely used for this purpose, due to its high sensitivity to larger particles, and its ability to resolve trace amounts of such particles from smaller entities (such as the API monomer). In addition, the DLS-derived dynamic virial coefficient can be used as a predictor of aggregation propensity, highly useful for formulation screening. This webinar will investgate how and why the Zetasizer range of instruments is widely used to carry out such types of analysis.